```html

Pseudomembranous Colitis – A Comprehensive Medical Guide

Overview

Pseudomembranous colitis (PMC) is an inflammation of the colon caused most often by an overgrowth of the bacterium Clostridioides difficile (formerly Clostridium difficile) after the normal gut flora has been disrupted, typically by antibiotics. The condition is characterized by the formation of a yellow‑white “pseudomembrane” that coats the colon’s lining, which can be seen during colonoscopy or autopsy.

Who it affects: Anyone who takes antibiotics can develop PMC, but it is most common in adults over 65, hospitalized patients, and those living in long‑term care facilities. Children can be affected, though rates are lower.

Prevalence: In the United States, the CDC reports ~462,000 healthcare‑associated C. diff infections (CDI) each year, resulting in ~29,000 deaths. Approximately 10‑20 % of CDI cases progress to pseudomembranous colitis, making the condition a significant public‑health concern.

Symptoms

Symptoms can range from mild to life‑threatening. Most appear within 5–10 days after the inciting antibiotic, but they may develop weeks later.

• Watery diarrhea – ≥3 loose stools in 24 hours; often foul‑smelling.
• Abdominal cramping or pain – usually lower abdomen, may be colicky.
• Fever – low‑grade (100‑102 °F) in mild disease, higher in severe cases.
• Loss of appetite & nausea.
• Dehydration – dry mouth, decreased urine output, dizziness.
• Blood or mucus in stool – occurs in 10‑15 % of patients.
• Weight loss – due to fluid loss and reduced intake.
• Elevated white‑blood‑cell count – a laboratory sign of systemic inflammation.

In severe disease, patients may develop:

• Severe abdominal distention (toxic megacolon)
• Signs of sepsis (rapid heart rate, low blood pressure)
• Kidney dysfunction from dehydration

Causes and Risk Factors

Primary cause

The majority of PMC cases are caused by a toxin‑producing strain of C. difficile. The bacterium releases two toxins (Toxin A & Toxin B) that damage the colon’s epithelial cells, leading to inflammation and pseudomembrane formation.

Key risk factors

• Recent or prolonged antibiotic use – especially clindamycin, fluoroquinolones, cephalosporins, and penicillins.
• Hospitalization or nursing‑home residence – close quarters facilitate spread.
• Advanced age – immune system less robust; 65+ accounts for ~70 % of severe cases.
• Immunocompromise – chemotherapy, organ transplantation, HIV/AIDS.
• Gastro‑intestinal surgery – especially colorectal procedures.
• Proton‑pump inhibitor (PPI) use – may alter stomach acidity and gut flora.
• Previous C. difficile infection – recurrence risk up to 20‑30 %.

Diagnosis

Prompt diagnosis is essential to prevent complications. Diagnostic steps typically include:

1. Clinical assessment

History of recent antibiotic exposure, characteristic diarrhea, and physical exam findings guide suspicion.

2. Laboratory tests

• Stool toxin assay – Enzyme immunoassay (EIA) or PCR detecting toxin genes; PCR is the most sensitive.
• Complete blood count (CBC) – May show leukocytosis (>15,000 cells/µL) in severe disease.
• Serum electrolytes & renal function – Assess dehydration and kidney impact.

3. Imaging (when severe)

• Abdominal X‑ray – Can reveal colonic dilation, ileus, or toxic megacolon.
• CT scan – Shows colonic wall thickening, “accordion sign,” and pericolonic fat stranding.

4. Endoscopy (reserved for ambiguous cases)

Flexible sigmoidoscopy or colonoscopy may reveal the classic yellow‑white pseudomembranes adherent to the mucosa. Biopsy confirms the diagnosis but is not required if stool testing is positive.

Treatment Options

Management aims to eradicate C. difficile, restore normal gut flora, and address complications.

1. Antibiotic therapy (targeted)

• First‑line: Oral vancomycin 125 mg four times daily for 10 days (or tapered/pulsed regimen for recurrent disease).
• Alternative: Fidaxomicin 200 mg twice daily for 10 days – comparable cure rates with lower recurrence.
• Metronidazole is now a second‑line option, reserved for mild disease when the above agents are unavailable.

IV vancomycin is NOT effective for colonic infection because it does not achieve therapeutic luminal concentrations.

2. Adjunctive therapies

• Fecal Microbiota Transplant (FMT) – Highly effective (~85‑90 % success) for ≥2 recurrences.
• Bezlotoxumab – A monoclonal antibody against toxin B; given as a single IV infusion to reduce recurrence in high‑risk patients.

3. Supportive care

• Aggressive fluid replacement (IV crystalloids) to correct dehydration.
• Electrolyte repletion (especially potassium and magnesium).
• Analgesia with acetaminophen; avoid NSAIDs that may aggravate colitis.

4. Surgical intervention

Indicated for fulminant disease (e.g., toxic megacolon, perforation, refractory shock). Options include subtotal colectomy with ileostomy. Surgery carries a 30‑40 % mortality rate, emphasizing the need for early escalation.

Living with Pseudomembranous Colitis

Even after acute symptoms resolve, many patients worry about recurrence and long‑term gut health. Below are practical tips:

Dietary guidance

• Stay hydrated – Aim for ≥2 L of fluid daily; oral rehydration solutions help replace electrolytes.
• Low‑residue, bland diet during flare‑ups (e.g., bananas, rice, applesauce, toast – the “BRAT” diet).
• Gradually re‑introduce fiber (soluble fiber such as oatmeal) once diarrhea improves.
• Limit sugary and high‑fat foods that can fuel harmful bacterial growth.

Medication management

• Keep a written list of antibiotics you have taken; share it with every healthcare provider.
• Ask about probiotic use; strains like Saccharomyces boulardii can reduce recurrence in some studies, but discuss with your doctor first.

Monitoring & follow‑up

• Schedule a stool test 2–4 weeks after treatment completion to confirm eradication (especially after severe disease).
• Watch for early signs of recurrence: new diarrhea, abdominal cramping, or fever.
• Maintain regular primary‑care or gastroenterology visits for at‑least 6 months post‑infection.

Psychosocial aspects

Frequent bathroom trips and fear of recurrence can cause anxiety. Consider counseling, support groups, or the CDC’s patient resources. Staying active within comfort limits improves overall well‑being.

Prevention

Because most cases are healthcare‑associated, prevention relies heavily on infection‑control practices.

• Antibiotic stewardship: Use antibiotics only when necessary, choose the narrowest effective spectrum, and keep courses as short as possible.
• Hand hygiene: Wash hands with soap and water (alcohol rubs do NOT kill C. difficile spores).
• Environmental cleaning: Hospitals should employ sporicidal agents (e.g., bleach) on high‑touch surfaces.
• Isolation precautions: Patients with confirmed CDI should be placed in contact isolation.
• Probiotic consideration: For high‑risk patients starting broad‑spectrum antibiotics, some clinicians recommend a probiotic, but evidence is mixed.

Complications

If left untreated or inadequately managed, PMC can progress to serious complications:

• Toxic megacolon – Acute colonic dilation (>6 cm) with systemic toxicity; mortality >30 % if surgery delayed.
• Colonic perforation – Leads to peritonitis and sepsis.
• Sepsis – From bacterial translocation or toxin‑mediated inflammation.
• Dehydration and acute kidney injury due to profuse diarrhea.
• Chronic bowel dysfunction – Persistent diarrhea, abdominal pain, or irritable‑bowel‑like symptoms after recovery.

When to Seek Emergency Care

---

References:
1. Centers for Disease Control and Prevention. Clostridioides difficile Infection (CDI) – Fact Sheet, 2024.
2. Mayo Clinic. Pseudomembranous colitis, 2023.
3. Wilson, K. et al. "Fidaxomicin vs Vancomycin for C. difficile Infection." New England Journal of Medicine, 2022.
4. Kelly, C.R., & LaMont, J.T. "Clostridioides difficile infection." New England Journal of Medicine, 2023.
5. WHO. Clostridioides difficile, 2022.
6. Cleveland Clinic. Pseudomembranous colitis, 2023.

```